How effective is tremelimumab?

Tremelimumab (tremelimumab) is an immune checkpoint inhibitor that is used to treat certain types of cancer, such as hepatocellular carcinoma (uHCC) and non-small cell lung cancer (NSCLC). However, evaluating the efficacy of temsitumumab needs to consider multiple factors, such as the patient's baseline condition, cancer type and stage, treatment regimen, etc. Texitumumab aims to enhance the immune response and inhibit tumor growth by inhibiting the signaling pathway in the immune system that inhibits T cell activity.

In a major study of patients with previously untreated advanced hepatocellular carcinoma whose cancer could not be removed with surgery, temsemumab plus imrvalumab was compared with standard treatment(sorafenib). The overall survival time of patients was increased. The average survival time of patients treated with temsitumumab combined with durvalumab was 16.4 months. About 20% of patients had tumors shrinking or disappearing. This response lasted for about 22 months on average.

In a major study of patients with metastatic NSCLC, 338 patients who received NSCLC combined with imrvalumab and chemotherapy lived an average of 14 months, while 337 patients who received chemotherapy alone lived an average of 12 months. They also lived longer without worsening of the disease, about6 months on average.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.